| Title |
Quarter Century of Anti-HIV CAR T Cells
|
|---|---|
| Published in |
Current HIV/AIDS Reports, March 2018
|
| DOI | 10.1007/s11904-018-0388-x |
| Pubmed ID | |
| Authors |
Thor A. Wagner |
| Abstract |
A therapy that might cure HIV is a very important goal for the 30-40 million people living with HIV. Chimeric antigen receptor T cells have recently had remarkable success against certain leukemias, and there are reasons to believe they could be successful for HIV. This manuscript summarizes the published research on HIV CAR T cells and reviews the current anti-HIV chimeric antigen receptor strategies. Research on anti-HIV chimeric antigen receptor T cells has been going on for at least the last 25 years. First- and second-generation anti-HIV chimeric antigen receptors have been developed. First-generation anti-HIV chimeric antigen receptors were studied in clinical trials more than 15 years ago, but did not have meaningful clinical efficacy. There are some reasons to be optimistic about second-generation anti-HIV chimeric antigen receptor T cells, but they have not yet been tested in vivo. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 73 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 19% |
| Student > Bachelor | 14 | 19% |
| Student > Master | 13 | 18% |
| Researcher | 7 | 10% |
| Other | 6 | 8% |
| Other | 7 | 10% |
| Unknown | 12 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 14 | 19% |
| Immunology and Microbiology | 14 | 19% |
| Agricultural and Biological Sciences | 12 | 16% |
| Medicine and Dentistry | 8 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Other | 6 | 8% |
| Unknown | 14 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2023.
All research outputs
#6,193,605
of 23,092,602 outputs
Outputs from Current HIV/AIDS Reports
#149
of 434 outputs
Outputs of similar age
#109,350
of 332,033 outputs
Outputs of similar age from Current HIV/AIDS Reports
#7
of 17 outputs
Altmetric has tracked 23,092,602 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 434 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,033 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.